TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05341492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR/B7H3 CAR-T
Description: 2 × 10\^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
Study: NCT06158347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen chamber
Description: Hyperbaric oxygen therapy allows patients to breathe 100% oxygen through an O2 Fresh M50 (HBOT Medical, Wonju, South Korea) chamber. Upon entering the chamber, oxygen is supplied by gradually increasing the barometric pressure from normal pressure to 1.5 atmospheres absolute (ATA).
Study: NCT06116110

Intervention type: OTHER
Intervention: Long-term Follow-Up
Description: No intervention
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT05243550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-102
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Study: NCT06062030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1609
Description: Drug of test group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC202304
Description: Drug of control group
Study: NCT04756063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Intravenous vitamin C

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT05413304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pre-operative abemaciclib
Description: pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
Study: NCT05272774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST+
Description: The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST+
Description: The intervention will be delivered as an online stress recovery intervention consisting of six weekly modules. Modules include an introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These modules have been chosen after considering the themes that could be most useful for healthcare workers under high stress. Each module consists of a psychoeducational and an exercise component.
Study: NCT05413304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device for Cerebral Fluid Dialysate Collection
Description: post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48-hours to assess CNS drug entry and targeted inhibition with abemaciclib

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ashion Analytics GEM ExTra
Description: resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib + temozolomide
Description: abemaciclib 150mg po BID and temozolomide 200mg/m2 po daily x 5 days in 28 day cycles (temozolomide 150mg/m2 po daily x 5 days for cycle 1)
Study: NCT04393181

Intervention type: PROCEDURE
Intervention: Heart transplantation 1
Description: Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study: NCT04393181

Intervention type: PROCEDURE
Intervention: Heart transplantation 2
Description: Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study: NCT06442917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: 32 the Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth was completed before the pregnancy intervention and the VAS was measured. Breathing exercise training and application were carried out during the latent phase process. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made.~During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed every 30 minutes from the beginning of contraction until the end of contraction. During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 15 minutes from the beginning of contraction to the end of contraction.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study: NCT04955795

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Brief Intervention (BI)
Description: The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
Study: NCT06442917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affirmation Method
Description: 32 pregnant women who were admitted to the hospital for childbirth and were in the latent phase (0-3 cm) filled out the pre-intervention Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth, and the VAS was measured. During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained. During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and the affirmation phrases were repeated and used by the researcher every 30 minutes from the beginning of the contraction until the end of the contraction.~During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and affirmation sentences and support sentences were said every 15 minutes from the beginning of the contraction to the end of the contraction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercise and Affirmation Method
Description: During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained and the application was made with breathing exercise training. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made. During the active phase process (4-7 cm), the Congenital Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 30 minutes from the beginning of contraction to the end of contraction, and the affirmation phrases were repeated and used by the researcher
Study: NCT04955795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (BI)
Description: The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA) via Telemedicine
Description: CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
Study: NCT06401330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05922423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
Study: NCT05200390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: FreeStyle Libre 2 system
Study: NCT05240859

Intervention type: DRUG
Intervention: Geleli
Description: Adalimumab Biosimilar
Study: NCT05709548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Subjects with a diagnosis of acute cholecystitis who undergo urgent laparoscopic cholecystectomy with the preoperative administration of indocyanine green (between 1-2 hours prior to surgery).
Study: NCT05064514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valved Stent Graft
Description: All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
Study: NCT06439953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate solution
Description: Evaluating the prophylactic use of Irrisept irrigation alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Evaluating the use of versus vancomycin-saline irrigation with or without topical vancomycin
Study: NCT04430517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
Study: NCT06334497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: 480mg (2X240mg- tablets) of Letermovir given orally once a day until the treatment success or the treatment failure, up to 12 weeks. In case of co-administration with cyclosporine A, the dosage of Letermovir will be reduced.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valganciclovir 900 mg (2X450 mg-tablets) twice a day until the treatment success or the treatment failure, up to 12 weeks. In case of impaired renal function, the dosage of valganciclovir will be reduced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir 900 mg (2X450 mg-tablets) twice a day until the treatment success or the treatment failure, up to 12 weeks. In case of impaired renal function, the dosage of valganciclovir will be reduced.
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04011787

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bolus NGT feeding
Description: Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Continuous NGT feeding
Description: Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: Both participant groups will have continuous glucose monitoring performed for 5 days while in the study

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Metabolic Profile
Description: Bloods will be taken to assess all patients metabolic profile

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic Profile
Description: Bloods will be taken to assess all patients metabolic profile

Intervention type: RADIATION
Group type: OTHER
Intervention: Chest X-ray
Description: A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chest X-ray
Description: A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
Study: NCT06445478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restrictive Exercise and Isokinetic Exercise
Description: Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restrictive Exercise and Isokinetic Exercise
Description: Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants.
Study: NCT06334497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letermovir placebo
Description: 480mg (2X240mg- tablets) of Letermovir placebo given orally once a day until the treatment success or the treatment failure, up to 12 weeks
Study: NCT05630469

Intervention type: OTHER
Intervention: Electroconvulsive therapy
Description: repetitive induction of a generalized seizure under controlled conditions (muscle relaxation and sedation)
Study: NCT06401330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI